Impel NeuroPharma Growth, Revenue, Number of Employees and Funding

Overview

Location:
Seattle, WA USA
Total Funding:$108M
Industry:Medical Equip
Founded:N/A
Lead Investor(s):KKR, Norwest Venture Partners
Press

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Impel NeuroPharma's estimated revenue is currently $14.8M per year.
  • Impel NeuroPharma received $67.5M in venture funding in December 2018.
  • Impel NeuroPharma's estimated revenue per employee is $235063
  • Impel NeuroPharma's total funding is $108M.

Employee Data

  • Impel NeuroPharma has 63 Employees.
  • Impel NeuroPharma grew their employee count by 34% last year.
  • Impel NeuroPharma currently has 2 job openings.

Executive Contacts

NameTitle
Lynn GoldSenior Vice President Regulatory Affairs
John HoekmanCo-Founder/Chief Scientific Officer
Scott YoumansSenior Vice President, Engineering
Christopher FullerAssociate Director, Engineering
Beatrix TaylorDirector of Regulatory Affairs
Jon CongletonPresident and CEO
Greg DaviesDirector Drug Development & Manufacturing
Jennifer BermanVice President, Marketing
Meghan SwardstromVice President Clinical Operations
Kelsey Hanson SatterlyDirector, Life Sciences

What Is Impel NeuroPharma?

Impel NeuroPharma, Inc., is a privately-held, Seattle-based company devoted to creating life-changing, innovative therapies for central nervous system (CNS) diseases. Impel's products are based on a novel nasal drug delivery platform, the POD device, that administers drug to the upper nasal cavity in a consistent and predictable manner. Impel NeuroPharma is currently investigating INP104 (POD DHE) for acute migraine headache, INP103 (POD levodopa) for Parkinson's Disease, INP105 (POD olanzapine) for agitation in schizophrenia and bipolar disorders as well as INP102 (POD insulin) for Alzheimer's disease in an NIH funded trial. Impel NeuroPharma's proprietary POD device enables small and large molecule drugs to be administered using a cost-effective, disposable, non-invasive intranasal drug delivery device. To learn more about Impel NeuroPharma, please visit our website at http://impelnp.com.

keywords:Biotechnology,Cleantech,Healthcare,Medical Devices,Pharmaceuticals,Wind Power

63

Number of Employees

$14.8M

Revenue (est)

2

Current Jobs

34%

Employee Growth %

$108M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Uptake Medical
$8M3470%$82.1M
Solta Medical
$63.5M2715%
EchoNous
$8M3417%$35M
Sawbones
$8.3M356%
Simulab Corpora...
$8.3M3517%
Summit Surgical
$16.3M7013%
Young Dental Ca...
$11M4715%
MicroSurgical T...
$23.1M982%
Kestra Medical ...
$13.6M5838%
Bardy Diagnosti...
$20.8M8946%$35M

Impel NeuroPharma News

07-Sep-19 - Impel NeuroPharma to Present Data From INP104 Clinical ...

SEATTLE, Sept. 5, 2019 /PRNewswire/ -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and ...

07-Sep-19 - Impel NeuroPharma Announces Last Patient Enrolled In ...

3, 2019 /PRNewswire/ -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of ...

07-Sep-19 - Impel NeuroPharma enrolls last patient in phase 3 migraine trial of INP104

Impel NeuroPharma announced the last patient has been enrolled in "STOP-301" (Safety and Tolerability of POD-DHE), the Company's pivotal ...

Impel NeuroPharma Funding

DateAmountRoundLead InvestorsReference
2013-11-29$2.6MUndisclosedArticle
2015-10-15$12.0MB3M New VenturesArticle
2016-09-01$1.1MUndisclosedArticle
2016-12-05$36.0MCvenBIOArticle
2018-12-07$67.5MDKKRArticle

Impel NeuroPharma Executive Hires

DateNameTitleReference
2017-10-04Jon CongletonPresident/CEOArticle
2018-07-17Lynn GoldSVP Regulatory AffairsArticle
2018-11-08Ellen LubmanChief Business OfficerArticle
2019-02-20Jennifer BermanVice President of MarketingArticle